Trintellix generic date?

When can we expect a generic version of Trintellix?

Trintellix, also known as vortioxetine, is a medication used to treat major depressive disorder. As the patent for Trintellix nears expiration, a generic version is expected to enter the market.

According to the patent search engine DrugPatentWatch.com, the patent for Trintellix (US9643146B2) is set to expire in 2029 [1]. However, it's worth noting that the FDA may approve a generic version before the patent expires through the 505(b)(2) pathway, which allows the agency to approve a generic version that doesn't require the same level of data as a brand-name drug.

What happens after the patent expires?

After the patent expires, other companies are likely to challenge Takeda Pharmaceutical's, the manufacturer of Trintellix, patent with a potential generic version. This process can take months or even years. However, companies typically begin developing a generic version before the patent expires, anticipating a smooth transition to the market.

Will a generic version of Trintellix be cheaper?

It is likely that a generic version of Trintellix will be more affordable than the brand-name version. The generic market competition drives prices down, making treatment more accessible to patients. However, the exact pricing remains uncertain until the generic version enters the market.

Other factors that may impact the generic version of Trintellix

Several factors can influence the availability and pricing of the generic version of Trintellix:

1. FDA approval: The FDA's timeline for reviewing generic applications can impact the availability of the generic version.
2. Litigation: Takeda Pharmaceutical may challenge the generic application in court, potentially delaying its release.
3. Market competition: Other generic manufacturers may enter the market, driving prices down and increasing competition.

Sources:

[1] DrugPatentWatch.com – US Patent No. 9643146B2 [https://www.drugpatentwatch.com/patent/US9643146B2]